pharmaphorum

DECEMBER 14, 2022

But increased competition is on the horizon. Sodium oxybate — which in the late 1980s was marketed to bodybuilders and then became known as GHB and criminally used as a date rape drug — has been sold under the brand name Xyrem after gaining FDA approval in 2002. Competition starts to heat up. Classic treatment options.

Competition 92

Competition FDA Pharmaceutical Marketing 92

Pharmaceutical Technology

OCTOBER 5, 2022

In 2009, former Biogen employee Michael Bawduniak filed a lawsuit claiming that Biogen had violated the False Claims Act and the Anti-Kickback Statute by providing millions of dollars to healthcare providers (HCPs) as an incentive to prescribe three of its multiple sclerosis (MS) drugs. BIIB107 is a monoclonal antibody that targets ?4

Government 59

Government Specialization Physicians Education 59

Evolve Your Success

JANUARY 23, 2024

The negotiation with the hospital, the shipping across boundaries, frontiers, FDA, and non-FDA is very interesting. Sometimes my competition will take that article and say, “I could plus or minus 10 millimeters.” It’s a very interesting business. There’s no better feeling than finding a home for all of your skillsets.

Medical sales 52

Medical sales Medical Sales Physicians 52

Pharmaceutical Technology

JANUARY 6, 2023

The agreement outlined that Par would keep its generic equivalent off the market for as many as two years, delaying the generic launch till September 30, 2014. In September, Novartis sent the FDA a petition, after a similar one was rejected in April 2021, asking for Entresto’s patent protection to be extended to February 2024.

Pharmaceutical 97

Pharmaceutical Doctors Healthcare Provider Prescription 97

Pharmaceutical Technology

MAY 26, 2023

The FDA has flagged this issue as pharmacies selling prescription drugs illegally have proliferated over the years. The US Food and Drug Administration (FDA commissioner Dr. Robert Califf says, “The illegal sale of prescription drug stimulants online puts Americans at risk and contributes to potential abuse, misuse, and overdose.”

Food and Drug Administration 52

Food and Drug Administration Prescription FDA Medical 52

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. In the US, obesity care is estimated at to cost $147 billion in healthcare spending annually. NICE has only allowed healthcare providers to prescribe continuous treatment of the drug for two years.

Medical 105

Medical Manufacturing Insurance Side effects 105

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. In the US, obesity care is estimated at to cost $147 billion in healthcare spending annually. NICE has only allowed healthcare providers to prescribe continuous treatment of the drug for two years.

Medical 98

Medical Manufacturing Insurance Side effects 98